CD8A and neoplasm: In recent years, blockade of immune checkpoint such as PD‐1/PD‐L1 has exhibited overwhelming success in the therapy of some kinds of cancers.[29] However, only a minority of patients responded well in the clinical trials.[30] It is reasonable that tumor cells with very low level of endogenous FAS expression may be still resistant to active CD8+ killer T cell‐executed death.